HMGB1 regulates autophagy through increasing transcriptional activities of JNK and ERK in human myeloid leukemia cells

  • Zhao, Mingyi (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Yang, Minghua (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Yang, Liangchun (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Yu, Yan (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Xie, Min (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Zhu, Shan (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Kang, Rui (Department of Pediatrics, Xiangya Hospital, Central South University) ;
  • Tang, Daolin (Hillman Cancer Center, University of Pittsburgh Cancer Institute) ;
  • Jiang, Zhigang (College of Life Sciences, Hunan Normal University) ;
  • Yuan, Wuzhou (College of Life Sciences, Hunan Normal University) ;
  • Wu, Xiushan (College of Life Sciences, Hunan Normal University) ;
  • Cao, Lizhi (Department of Pediatrics, Xiangya Hospital, Central South University)
  • Received : 2011.05.24
  • Accepted : 2011.07.18
  • Published : 2011.09.30


HMGB1 is associated with human cancers and is an activator of autophagy which mediates chemotherapy resistance. We here show that the mRNA levels of HMGB1 are high in leukemia cells and it is involved in the progression of childhood chronic myeloid leukemia (CML). HMGB1 decreases the sensitivity of human myeloid leukemia cells K562 to anti-cancer drug induced death through up-regulating the autophagy pathway, which is confirmed by the observation with an increase in fusion of autophagosomes and autophagolysosomes. When overexpressing HMGB1, both mRNA levels of Beclin-1, VSP34 and UVRAG which are key genes involved in mammalian autophagy and protein levels of p-Bcl-2 and LC3-II are increased. Luciferase assays document that over-expression of HMGB1 increases the transcriptional activity of JNK and ERK, which may be silenced by siRNA. The results suggest that HMGB1 regulates JNK and ERK required for autophagy, which provides a potential drug target for therapeutic interventions in childhood CML.



  1. Tang, D., Kang, R., Zeh, H. J. and Lotze, M. T. (2010) High-mobility group box 1 and cancer. Biochim. Biophys. Acta. 1799, 131-140.
  2. Tang, D., Kang, R., Livesey, K. M., Cheh, C. W., Farkas, A., Loughran, P., Hoppe, G., Bianchi, M. E., Tracey, K. J., Zeh III, H. J. and Lotze, M. T. (2010) Endogenous HMGB1 regulates autophagy. JCB 6, 881-892.
  3. Mizushima, N., Levine, B. and Cuervo, A. M. (2008) Autophagy fights disease through cellular self-digestion. Nature 451, 1069-1075.
  4. Levine, B. and Kroemer, G. (2008) Autophagy in the pathogenesis of disease. Cell. 132, 27-42.
  5. Livesey, K. M., Tang, D. L. and Zeh, H. J. (2009) Autophagy inhibition in combination cancer treatment. Curr. Opin. Investig. Drugs. 10, 1269-1279.
  6. Carew, J. S., Nawrocki, S. T., Kahue, C. N., Zhang, H., Yang, C. Y., Chung, L., Houghton, J. A., Huang, P., Giles, F. J. and John, L. (2007) Clevel and targeting lysosomal degradation induces p53-dependent cell death and prevents cancer in mouse models of lymphomagenesis. Clin. Invest. 110, 313-322.
  7. Xie, M., Kang, R. and Yu, Y. (2008) Enhancive effect of HMGB1 gene silence on adriamycin-Induced apoptosis in K562/A02 drug resistance leukemia cells. J. Zhonghua. Xue. Ye. Xue. Za. Zhi. 21, 549-552.
  8. Yu, Y., Xie, M. and He, Y. L. (2008) Role of high mobility group box 1 in adriamycin-induced apoptosis in leukemia K562 cells. Ai. Zheng. 27, 929-933.
  9. Liu, L. Y., Yang, M. H. and Kang, R. (2011) HMGB1- induced autophagy promotes chemotherapy resistance in leukemia cells. Leukemia. 25, 23-31.
  10. Fan, X. W., Yang, Q., Wang, Y. L. and Wu, X. S. (2010) Cloning and characterization of the cardiac-specific Lrrc10 promoter. J. BMB Rep. 27, 123-128.
  11. Hanahan, D. and Weinberg, R. A. (2000) The hallmarks of cancer. Cell 100, 57-70.
  12. Funderburk, S. F., Wang, Q. J. and Yue, Z. Y. (2010) The Beclin1-VPS34-complex - at the cross roads of autophagy and beyond. Cell. Biology. 20, 355-362.
  13. Kang, R., Livesey, K. M., Zeh, H. J., Lotze, M. T. and Tang, D. L. (2010) HMGB1 -A novel Beclin 1-binding protein active in autophagy. Autophagy. 16, 1209-1211.
  14. Mizushima, N., Yoshimori, T. and Levine B. (2010) Methods in mammalian autophagy research. Cell. 140, 313-326.
  15. Liu, L. Y., Yang, M. H., Kang, R., Wang, Z., Zhao, M. Y., Yu, Y., Xie, M., Yin, X. C., Livesey, K. M., Lotze, M. T., Tang, D. L. and Cao, L. Z. (2011) DAMP-mediated autophagy contributes to drug resistance. Autophagy. 7, 112-114.

Cited by

  1. HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer vol.36, pp.11, 2015,
  2. Drug Screening for Autophagy Inhibitors Based on the Dissociation of Beclin1-Bcl2 Complex Using BiFC Technique and Mechanism of Eugenol on Anti-Influenza A Virus Activity vol.8, pp.4, 2013,
  3. The novel BH-3 mimetic apogossypolone induces Beclin-1- and ROS-mediated autophagy in human hepatocellular cells vol.4, pp.2, 2013,
  4. Autophagy-mediated HMGB1 release promotes gastric cancer cell survival via RAGE activation of extracellular signal-regulated kinases 1/2 vol.33, pp.4, 2015,
  5. HMGB1 Promotes Mitochondrial Dysfunction–Triggered Striatal Neurodegeneration via Autophagy and Apoptosis Activation vol.10, pp.11, 2015,
  6. Expression of cFLIPLDetermines the Basal Interaction of Bcl-2 With Beclin-1 and Regulates p53 Dependent Ubiquitination of Beclin-1 During Autophagic Stress vol.117, pp.8, 2016,
  7. JNK confers 5-fluorouracil resistance in p53-deficient and mutant p53-expressing colon cancer cells by inducing survival autophagy vol.4, pp.1, 2015,
  8. Synergistic effect of HMGB1 knockdown and cordycepin in the K562 human chronic myeloid leukemia cell line vol.12, pp.3, 2015,
  9. Krüppel-like factor 4 promotes high-mobility group box 1-induced chemotherapy resistance in osteosarcoma cells vol.107, pp.3, 2016,
  10. Digital gene expression profiling analysis of childhood acute lymphoblastic leukemia vol.13, pp.5, 2016,
  11. Inhibition of JNK-1 by small interfering RNA induces apoptotic signaling in PC-3 prostate cancer cells vol.30, pp.4, 2012,
  12. HMGB1 modulates Lewis cell autophagy and promotes cell survival via RAGE-HMGB1-Erk1/2 positive feedback during nutrient depletion vol.220, pp.5, 2015,
  13. Kinases Involved in Both Autophagy and Mitosis vol.18, pp.9, 2017,
  14. HMGB1 in health and disease vol.40, 2014,
  15. HMGB1-dependent and -independent autophagy vol.10, pp.10, 2014,
  16. The Role of Autophagy in Usnic Acid-Induced Toxicity in Hepatic Cells vol.142, pp.1, 2014,
  17. Targeting microRNA-30a-mediated autophagy enhances imatinib activity against human chronic myeloid leukemia cells vol.26, pp.8, 2012,
  18. p38 and JNK MAPK pathways control the balance of apoptosis and autophagy in response to chemotherapeutic agents vol.344, pp.2, 2014,
  19. Targeting Chronic Myeloid Leukemia Stem Cells vol.8, pp.1, 2013,
  20. Activation of the HMGB1-RAGE axis upregulates TH expression in dopaminergic neurons via JNK phosphorylation 2017,
  21. Inhibiting autophagy potentiates the anticancer activity of IFN1@/IFNα in chronic myeloid leukemia cells vol.9, pp.3, 2013,
  22. Regulation of the Autophagic Bcl-2/Beclin 1 Interaction vol.1, pp.4, 2012,
  23. Autophagy and chemotherapy resistance: a promising therapeutic target for cancer treatment vol.4, pp.10, 2013,
  24. Role of plasma high mobility group box-1 in disseminated intravascular coagulation with leukemia vol.136, pp.2, 2015,
  25. Autophagy and Inflammatory Response in the Tumor Microenvironment vol.18, pp.9, 2017,
  26. Spautin-1, a novel autophagy inhibitor, enhances imatinib-induced apoptosis in chronic myeloid leukemia vol.44, pp.5, 2014,
  27. Ambra1 in autophagy and apoptosis: Implications for cell survival and chemotherapy resistance vol.12, pp.1, 2016,
  28. FGF10 Protects Against Renal Ischemia/Reperfusion Injury by Regulating Autophagy and Inflammatory Signaling vol.9, pp.1664-8021, 2018,
  29. Autophagy: Dual Response in the Development of Hepatocellular Carcinoma vol.8, pp.2, 2019,